Boston, MA -- (SBWIRE) -- 09/10/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Santarus, Inc. (NASDAQ:SNTS), Intrepid Potash, Inc. (NYSE:IPI), ARMOUR Residential REIT, Inc.(NYSE:ARR), Trius Therapeutics, Inc.(NASDAQ:TSRX)
Santarus, Inc. (NASDAQ:SNTS) stock decreased 2.96% to $22.29. The company announced that Gerald T. Proehl, president and chief executive officer, will make presentations at the following investment conferences: Morgan Stanley Global Healthcare Conference on September 10, 2013, at 3:30 p.m. Eastern time (12:30 p.m. Pacific time) in New York City, and Stifel Nicolaus Healthcare Conference on September 11, 2013, at 2:05 p.m. Eastern time (11:05 a.m. Pacific time) in Boston.
How Should Investors Trade SNTS After The Recent Volatility? Get Free Report Here
Intrepid Potash, Inc. (NYSE:IPI) shares jumped 7.90% to $13.93. IPI’s stock had its target price reduced by Barclays Capital from $13.00 to $12.00 in a report issued on August 12.
Additionally, the company on July 31 reported financial results for the second quarter of 2013. The company posted second quarter net income of $11.3 million, or $0.15 per share, compared with second quarter 2012 net income of $19.0 million, or $0.25 per share. Adjusted net income was $12.7 million, or $0.17 per share, compared with $18.8 million, or $0.25 per share, in the same period of the prior year.
How Should Investors Trade IPI After The Recent Volatility? Get Free Report Here
ARMOUR Residential REIT, Inc.(NYSE:ARR) shares climbed 0.95% to $4.23. The company on August 27 announced that the Board of Directors has appointed Ms. Carolyn Downey as a new independent member of the Board of Directors of the Company, effective September 3, 2013.
With the appointment of Ms. Downey, the Company expects to regain compliance with Section 303A.01 of the New York Stock Exchange Listed Company Manual and Section 802(a) of the NYSE MKT LLC Company Guide, both which require a majority of independent directors on the Company's Board of Directors.
Is ARR A Good Buy After The Recent Price Movement? Find Out Here
Trius Therapeutics, Inc.(NASDAQ:TSRX) shares decreased 0.72% to $13.71. The company on Sept. 6 announced that results of clinical studies of its lead antibiotic candidate, tedizolid phosphate, will be presented this week at the 53rdInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Denver. Seven poster and slide sessions regarding tedizolid have been accepted for presentation. Trius researchers will also present a poster on cfr resistance and two poster sessions on the company's GyrB/ParE antibacterial program, which targets Gram-negative pathogens.
Is TSRX A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)